Skip to main content

Table 1 Patient demographics, selected laboratory values, clinical history, and immunotherapy drugs included in this study

From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Age
 Median 53.5
 Range 18–84
Sex
 Female 29
 Male 21
No. of metastatic sites
  < 3 37
  > =3 13
LDH
  < =ULN 36
  > ULN 14
ECOG PS
 0–1 48
 2 2
Albumin
  > =3.5 g/dl 46
  < 3.5 g/dl 4
RMH score
  < 2 43
  > =2 7
Prior treatments
 Median 3
 Range 0–12
 Anthracycline 30
 Ifosfamide 14
 Gemcitabine 22
 Docetaxel 13
 Platinum 8
Investigational therapies
 anti-CCR4 and anti-PD-L1 4
 anti-PD-1 7
 anti-PD-L1 7
 anti-TIM-3 1
 anti-CTLA-4 5
 anti-CTLA-4 and immunomodulator 7
 anti-CTLA-4 and KIT inhibitor 10
 Dendritic cell vaccine 7
 Interleukin-2 1
 anti-TGF-β 1